We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, […]

  We franchise and operate retail stores under brand name “Jiuzi”, which sell new energy vehicles, or NEVs, in third-fourth tier cities in China. Almost all of the NEVs we sell are battery-operated electric vehicles. We also sell a few plug-in electric vehicles upon demand from vehicle buyers. As of the date of this prospectus, […]

  We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. Although we may acquire a business in any industry, we intend to focus […]

  We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Our approach is designed to augment neuronal growth factor signaling through […]

(Note:  This is not a traditional IPO. This is a direct listing of our Class A common stock on the New York Stock Exchange without the involvement of any investment bank.  From the prospectus: “We have engaged Morgan Stanley & Co. LLC, or Morgan Stanley; J.P. Morgan Securities LLC, or J.P. Morgan; Credit Suisse Securities […]

  Ribbit LEAP, Ltd., which stands for Ribbit Capital Long-Term Equity Acquisition Pool, is a newly organized blank check company incorporated in the Cayman Islands.  While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus our search for an initial business combination in the intersection of financial […]

(Note: Cohn Robbins Holdings Corp. was formerly known as CSR Acquisition Corp.. which was a newly organized blank check company that had filed to go public on July 31, 2020; that IPO was 30 million units at $10 each. The name change is disclosed in the S-1/A filing on Aug. 25, 2020. In this filing, […]

  We are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. We are utilizing our proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. Using our FORCE platform, we are assembling a broad portfolio […]

While we may pursue an initial business combination in any industry, we intend to focus our efforts on businesses that leverage our management team’s experience in acquiring and operating businesses in the consumer (“Consumer”) as well as technology, media and telecommunications (“TMT”) industries. We intend to focus our efforts and will seek to capitalize on […]

(Note: This is not a traditional IPO. This is a direct listing of Palantir’s Class A common stock on the New York Stock Exchange without the involvement of underwriters. From the prospectus: “We have engaged Morgan Stanley & Co. LLC (“Morgan Stanley”), Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC, Allen & Company […]